Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

The World Health Organisation recommended dolutegravir (DTG)-based antiretroviral therapy (ART) regimens are available but not reimbursed through the public reimbursement system in China. The objective of this analysis was to evaluate the cost-effectiveness of DTG (DTG + TDF/3TC) compared to efavire...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cost effectiveness and resource allocation 2019-12, Vol.17 (1), p.26-26, Article 26
Hauptverfasser: Punekar, Yogesh Suresh, Guo, Na, Tremblay, Gabriel, Piercy, James, Holbrook, Tim, Young, Benjamin
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
AIDS
Anti-HIV agents
Antiretroviral agents
Antiretroviral drugs
Biological products industry
China
Comorbidity
Comparative analysis
Cost analysis
Cost benefit analysis
Cost effectiveness
Darunavir
Dolutegravir
Drug therapy
Economic analyses
Economic aspects
Efavirenz
Failure
Funding
Health
Highly active antiretroviral therapy
HIV
HIV patients
Human immunodeficiency virus
Lopinavir
Markov processes
Medical research
Mortality
Patients
Public health
Raltegravir
Regulatory approval
Reverse transcriptase inhibitors
RNA
Treatment naive
World health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The World Health Organisation recommended dolutegravir (DTG)-based antiretroviral therapy (ART) regimens are available but not reimbursed through the public reimbursement system in China. The objective of this analysis was to evaluate the cost-effectiveness of DTG (DTG + TDF/3TC) compared to efavirenz (EFV + TDF/3TC) in treatment-naive and ritonavir-boosted lopinavir (LPV/r + TDF/3TC) in first-line ART failure HIV-1-infected patients in China. A dynamic Markov model comprising of 5 response states and 6 CD4+ count-based health states was used. Efficacy, estimated as probability of virologic suppression (HIV RNA
ISSN:1478-7547
1478-7547
DOI:10.1186/s12962-019-0195-2